2024
The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections
Ivasiy R, Madden L, DiDomizio E, Johnson K, Machavariani E, Ahmad B, Oliveros D, Ram A, Kil N, Altice F. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections. Drug And Alcohol Dependence 2024, 263: 112410. PMID: 39159600, DOI: 10.1016/j.drugalcdep.2024.112410.Peer-Reviewed Original ResearchOpioid use disorderXR-NTXUse disorderHCV infectionPrescribed MOUDOpioid use disorder cascadePrevalence of opioid use disorderRetrospective cohort studyHigher treatment retentionCascade of careConcurrent infectious diseasesSix-month retentionHCV/HIV coinfectionComorbid HIVCohort studyHospital-based settingPrescribed methadoneHCVMOUD initiationHIVHCV epidemicOpioidMethadoneMOUD prescriptionsTreatment retention
2023
Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias
DiDomizio E, Chandra D, Nichols L, Villanueva M, Altice F. Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias. Health Promotion Practice 2023, 24: 998-1008. PMID: 37440258, DOI: 10.1177/15248399231169928.Peer-Reviewed Original ResearchConceptsNominal group techniqueHealth care decisionsProvider perspectivesEligibility criteriaHIV/HCVEffective antiviral medicationsPatient eligibility criteriaFacilitators of treatmentMicro-EliminationHCV treatmentAntiviral medicationsOpioid epidemicProvider knowledgePatient involvementPatient engagementDifferent clinicsRelated stigmaHCVCare decisionsHIVPatientsTreatmentGroup sessionsMost barriersFocus group sessions
2021
HIV/AIDS, hepatitis and tuberculosis-related mortality among incarcerated people: a global scoping review.
Bosworth R, Borschmann R, Altice FL, Kinner SA, Dolan K, Farrell M. HIV/AIDS, hepatitis and tuberculosis-related mortality among incarcerated people: a global scoping review. International Journal Of Prison Health 2021, 18: 66-82. PMID: 35401772, PMCID: PMC8992694, DOI: 10.1108/ijph-02-2021-0018.Peer-Reviewed Original ResearchConceptsInfectious disease-related mortalityDisease-related mortalityHIV/AIDSInfectious diseasesInfectious disease-related deathsTB-related deathsTuberculosis-related mortalityHIV/TBDisease-related deathScoping ReviewPublic health benefitsNumber of deathsGlobal scoping reviewPreventable mortalityHigh riskHCVMortalityCustodial settingsHBVFirst scoping reviewMortality dataAvailable evidenceDeath rateHealth benefitsDeath
2020
Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States
Zelenev A, Li J, Shea P, Hecht R, Altice FL. Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States. Clinical Infectious Diseases 2020, 72: 755-763. PMID: 32060534, PMCID: PMC7935393, DOI: 10.1093/cid/ciaa142.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySyringe services programHepatitis C virus (HCV) treatmentC virus treatmentHCV prevalenceHCV microeliminationHCV TasPHCV treatmentPrevention strategiesVirus treatmentTasP strategyHigh HCV prevalenceMicroelimination of HCVHuman immunodeficiency virusHCV treatment coverageOAT coverageAgonist therapyImmunodeficiency virusTreatment coverageMicroeliminationPrevention impactPrevalenceComplimentary interventionsHCVPWID
2019
Prisons: ignore them at our peril.
Kamarulzaman A, Verster A, Altice FL. Prisons: ignore them at our peril. Current Opinion In HIV And AIDS 2019, 14: 415-422. PMID: 31343458, PMCID: PMC7137098, DOI: 10.1097/coh.0000000000000572.Peer-Reviewed Original ResearchConceptsMedication-assisted therapyDrug useHIV prevention toolPrevalence of HIVMedication-assisted treatmentSyringe services programCriminal justice settingsBasic healthcareMiddle-income settingsHCV preventionOpioid dependenceTreatment strategiesHigh prevalenceOverdose managementRoutine screeningPrevention servicesHIVKey populationsMental healthcareHCVConsolidated guidelinesPrevention toolJustice settingsTreatmentEffective screening
2018
Estimating HIV and HCV prevalence among people who inject drugs in 5 Ukrainian cities using stratification-based respondent driven and random sampling
Zelenev A, Shea P, Mazhnaya A, Meteliuk A, Pykalo I, Marcus R, Fomenko T, Prokhorova T, Altice FL. Estimating HIV and HCV prevalence among people who inject drugs in 5 Ukrainian cities using stratification-based respondent driven and random sampling. International Journal Of Drug Policy 2018, 67: 91-101. PMID: 30503695, PMCID: PMC6537868, DOI: 10.1016/j.drugpo.2018.09.010.Peer-Reviewed Original ResearchConceptsHCV prevalenceHIV prevalenceHCV prevalence estimatesHigh HCV prevalencePrevalence of HIVCross-sectional studyLow-resource settingsInverse probability weightsHCV antibodiesHCV infectionTreatment strategiesHIVTreatment prioritiesPrevalence estimatesHealth outcomesBetter preventionPrevalenceLocal epidemicsHCVPWIDOverall sampleSelection biasPreventionProbability weightsRegular basisHepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine
Iakunchykova O, Meteliuk A, Zelenev A, Mazhnaya A, Tracy M, Altice FL. Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine. International Journal Of Drug Policy 2018, 57: 11-17. PMID: 29655101, PMCID: PMC5994183, DOI: 10.1016/j.drugpo.2018.03.022.Peer-Reviewed Original ResearchConceptsAnti-HCV testIndependent correlatesHCV testingPositive statusAnti-HCV positive statusAnti-HCV positivityHCV treatment cascadeHCV-positive statusOpioid-dependent PWIDRegular HCV testingHIV-negative participantsPositive test resultsChronic HCVHCV prevalenceStatus awarenessHCV infectionHCV preventionTreatment cascadeTreatment strategiesTreatment utilizationNegative participantsPWIDTreatment experienceHCVConfirmatory testing
2016
THU-225 C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist Therapy
Arduino J, Shibolet O, Litwin A, Grebeley J, Altice F, Nwankwo C, Mast T, Jiang Z, Gendrano I, Platt H, Dore G. THU-225 C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist Therapy. Journal Of Hepatology 2016, 64: s403-s404. DOI: 10.1016/s0168-8278(16)00638-3.Peer-Reviewed Original Research
2014
Strategies for Hepatitis C Testing and Linkage to Care for Vulnerable Populations: Point-of-Care and Standard HCV Testing in a Mobile Medical Clinic
Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for Hepatitis C Testing and Linkage to Care for Vulnerable Populations: Point-of-Care and Standard HCV Testing in a Mobile Medical Clinic. Journal Of Community Health 2014, 39: 922-934. PMID: 25135842, PMCID: PMC8317466, DOI: 10.1007/s10900-014-9932-9.Peer-Reviewed Original ResearchConceptsHCV testing strategyMobile medical clinicHCV testingHCV careHCV treatmentPatient preferencesPOC testingPrior injection drug useMedical clinicsHepatitis C testingReactive test resultsInjection drug useRoutine health assessmentsPrior STI diagnosisTesting strategiesHCV prevalenceStandard phlebotomySTI diagnosisTherapeutic advancesSpecialty clinicSerological testingWhite raceC testingDrug useHCV
2013
The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting
Morano JP, Gibson BA, Altice FL. The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting. PLOS ONE 2013, 8: e64321. PMID: 23691197, PMCID: PMC3653872, DOI: 10.1371/journal.pone.0064321.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHCV coinfectionHIV monoinfectionTransmission risk behaviorsCross-sectional studyMobile medical clinicViral infection statusCrack cocaine useHCV monoinfectionHCV infectionIndependent correlatesCoinfection statusLifetime HIVClinical careHCVHIVMonoinfectionElectronic databasesDisease preventionCocaine useMedical clinicsRisk behaviorsGallery useInfection statusCoinfection
2004
Hepatitis C virus infection in United States correctional institutions
Altice F, Bruce R. Hepatitis C virus infection in United States correctional institutions. Current Hepatology Reports 2004, 3: 112-118. DOI: 10.1007/s11901-004-0018-5.Peer-Reviewed Original ResearchHepatitis C virus infectionC virus infectionInjection drug usersVirus infectionDrug usersRisk reduction interventionsCurable infectionEffective therapyHigh prevalenceCare approachHigh riskReduction interventionsMental illnessSexual partnersInfectionHealth carePublic healthCorrectional settingsSettingHCVIdeal settingHIVTherapyIllnessPrevalence
2002
Safer Injection Facilities in North America: Their Place in Public Policy and Health Initiatives
Broadhead R, Kerr T, Grund J, Altice F. Safer Injection Facilities in North America: Their Place in Public Policy and Health Initiatives. Journal Of Drug Issues 2002, 32: 329-355. DOI: 10.1177/002204260203200113.Peer-Reviewed Original ResearchSafer injection facilityHealth initiativesDrug treatmentInjection-related health problemsNeedle exchange programsDrug-using communityPublic health initiativesPublic health programsHealth care programsDrug injectionDrug overdoseDrug injectorsMortality rateCare programNeedle exchangeHealth problemsMedical careHealth programsInjection facilitiesInnovative interventionsTimely contactTreatmentHCVHIVOverdose